We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

67 hedge funds and large institutions have $19.6M invested in Cardiff Oncology in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more call options, than puts

Call options by funds: $445K | Put options by funds: $385K

17.54% less ownership

Funds ownership: 38.16% → 20.62% (-18%)

26% less funds holding

Funds holding: 91 → 67 (-24)

42% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 26

52% less capital invested

Capital invested by funds: $41M → $19.6M (-$21.3M)

69% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 32

Holders
67
Holders Change
-24
Holders Change %
-26.37%
% of All Funds
1.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
15
Reduced
26
Closed
32
Calls
$445K
Puts
$385K
Net Calls
+$60K
Net Calls Change
+$180K

Top Buyers

1
LCM
Laurion Capital Management
New York
+$1.21M
2
Renaissance Technologies
Renaissance Technologies
New York
+$396K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$365K
4
CIP
Chartwell Investment Partners
Pennsylvania
+$361K
5
E
Ergoteles
New York
+$308K

Top Sellers

1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$4.32M
2
EAM
Eventide Asset Management
Massachusetts
-$3.64M
3
BlackRock
BlackRock
New York
-$3.06M
4
State Street
State Street
Massachusetts
-$945K
5
Citadel Advisors
Citadel Advisors
Florida
-$792K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
76
California State Teachers Retirement System (CalSTRS)
California
– -$41K -16,448 Closed
VOYA Investment Management
77
VOYA Investment Management
Georgia
– -$36K -14,452 Closed
Invesco
78
Invesco
Georgia
– -$26K -10,456 Closed
Manulife (Manufacturers Life Insurance)
79
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$25.7K -10,353 Closed
UBS Group
80
UBS Group
Switzerland
– -$11.6K -6,942 -99%
Barclays
81
Barclays
United Kingdom
– -$10.4K -6,184 -100%
AB
82
Amalgamated Bank
New York
– -$11K -4,585 Closed
PFS
83
Prospera Financial Services
Texas
– -$10K -4,085 Closed
Legal & General Group
84
Legal & General Group
United Kingdom
– -$7K -2,886 Closed
AIP
85
Ameritas Investment Partners
Nebraska
– -$7K -2,835 Closed
PHK
86
Point72 Hong Kong
Hong Kong
– -$5K -2,154 Closed
Nisa Investment Advisors
87
Nisa Investment Advisors
Missouri
– -$5K -2,130 Closed
Koshinski Asset Management
88
Koshinski Asset Management
Illinois
– -$2.48K -1,000 Closed
ACM
89
Aquatic Capital Management
Illinois
– -$2K -700 Closed
CS
90
Credit Suisse
Switzerland
– +$33 +20 New
TWA
91
TCI Wealth Advisors
Arizona
– +$167 +100 New
Rockefeller Capital Management
92
Rockefeller Capital Management
New York
– +$261 +156 +2,229%
1 2 3
4

CRDF Hedge Fund Activity: Q2 2022 in Review

67 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q2 2022, worth a combined $19.6M — down 52% from $41M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of CRDF and 10 opened new positions — a net loss of 22 holders — while 26 trimmed existing stakes and 15 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $1.21M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $4.32M sold.

  • 67 institutional investors held Cardiff Oncology (CRDF) as of Q2 2022, down from 91 in Q1 2022.
  • Funds reported $19.6M of Cardiff Oncology stock for Q2 2022, down 52% quarter-over-quarter.
  • 10 funds opened new Cardiff Oncology positions in Q2 2022 and 32 closed out, a net change of -22 holders.
  • The largest Cardiff Oncology buyer in Q2 2022 was Laurion Capital Management, an estimated $1.21M added.
  • The largest Cardiff Oncology seller in Q2 2022 was Janus Henderson Group, an estimated $4.32M sold.

Based on aggregated 13F filings for Q2 2022.